More Articles

Generic pre-emption raises its ugly head again Policies & Legislation | Posted 07/12/2012

The US Supreme Court is to review a case, which could determine whether generics companies can be held responsible for design flaws in the drugs they copy.

China-based Innovent gains funding for expansion Biosimilars/News | Posted 07/12/2012

Innovent Biologics (Innovent) has raised US$25 million in Series B financing to put towards the continued expansion of its pipeline and manufacturing capabilities.

Ranbaxy not the only Indian generics maker subject to FDA recalls Generics/News | Posted 07/12/2012

It seems that Ranbaxy Pharmaceuticals (Ranbaxy) is not the only Indian generics manufacturer who has been subjected to FDA recalls. It now comes to light that Dr Reddy’s Laboratories (Dr Reddy’s) a...

Marvel withdraws biosimilar insulin applications Biosimilars/News | Posted 07/12/2012

EMA announced on 27 November 2012 that it had been informed by Marvel LifeSciences (Marvel) that the company would be withdrawing its authorization applications for its three biosimilar human insul...

Eli Lilly and Strides Arcolab in generics deal Pharma News | Posted 07/12/2012

Pharma giant Eli Lilly and India-based generics manufacturer Strides Arcolab announced on 5 December 2012 a collaboration to market the latter’s generic cancer drugs in emerging markets.

Overview of research on ‘general’ policies aimed at generics in 2012 Generics/Research | Posted 30/11/2012

Period: January to August 2012 Many governments around the world already have policies in place to promote the use of generic medicines, and with the increasing cost of health care and restric...

Approval of first biosimilar G-CSF in Japan Biosimilars/News | Posted 30/11/2012

Mochida Pharmaceuticals (Mochida) and development partner Fuji Pharma announced on 21 November 2012 that they had gained approval for the first biosimilar granulocyte colony-stimulating factor (G-C...

The ethics of generic drug liability Generics/Research | Posted 30/11/2012

What responsibility should the manufacturers of generic medicines bear for warnings about adverse effects of their medicines? Indeed, what responsibility should be borne by the original manufacture...